Acumen pharmaceuticals presents sabirnetug (acu193) fluid biomarker and target engagement analyses from phase 1 intercept-ad study in early alzheimer's at the ad/pd™ 2024 annual meeting

- cerebrospinal fluid (csf) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the brain in early ad

ABOS Ratings Summary

ABOS Quant Ranking